Navigation Links
Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Date:5/16/2012

ication of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation aff
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
2. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
3. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
6. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
7. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
8. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Dyax Corp.,(Nasdaq:DYAX) announced today positive topline results ... its lead product,candidate DX-88 (ecallantide), for hereditary ... data is scheduled for Tuesday,April 17, 2007 ... discovered, recombinant, plasma kallikrein,inhibitor, is in clinical ...
... 2007 - In a late-breaker,presentation at the ... the Study of the Liver (EASL), researchers ... of the PROVE 1 clinical trial,which is ... with,the investigational hepatitis C protease inhibitor telaprevir ...
Cached Medicine Technology:DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 2DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 3DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 4DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2
... LAKE FOREST, Ill. and MINNEAPOLIS , ... Fitness Corporation (NYSE AMEX: FIT ) today announced that ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in ...   http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , On January 21, 2010 , ...
... WASHINGTON , Feb. 5 In response ... today, the American Veterinary Medical Association (AVMA) is reaffirming its ... help maintain and improve the health of U.S. livestock. , ... creating a new strategy for animal disease traceability. This comes ...
... ... San Francisco,s famed PIER 39 docks, was successfully rescued, rehabilitated and released back to the ... assembled at Rodeo Beach in the Marin Headlands, Sausalito, CA to watch as "Abagnale" made ... ...
... focus of new laws, online testing and Super Bowl plug ... improve treatment of concussions in youth sports are making headway ... in scholastic sports will get big play Sunday at Super ... can help athletic trainers and doctors determine when it,s safe ...
... LOS ANGELES , Feb. 5 Food 4 ... to support children,s hospitals in the communities its stores serve in ... Chicago area. In addition, the supermarket chain,s Foods Co ... California . , Customers and team members can support their ...
... Finding may further understanding of common diseases, researchers say , ... map of areas of the human genome that control which ... a finding that may advance understanding of the genetic ... the human genome is uncharted territory -- entire stretches of ...
Cached Medicine News:Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4Health News:AVMA Calls for Stronger Animal Disease Traceability System 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 3Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 4Health News:Concussion Awareness for Young Athletes Gets Big Play 2Health News:Food 4 Less Charitable Campaign to Benefit Children's Hospitals 2
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... Endotracheal Tube w. FlexiSlip™ Stylet, Murphy eye. Tube ... Rusch endotracheal tube with a preloaded Flexi-Slip Stylet ... storage space. The stylet has a low friction ... with a soft distal tip to reduce the ...
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
... Ruschelit® PVC. Murphy eye-oral. High ... Graduated. Oral Cuffed Single use. For ... kinking of the tube by incorporating ... low-pressure cuff. Thermosensitive Ruschelit® PVC adapts ...
Medicine Products: